INT10843

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.22
First Reported 1980
Last Reported 2005
Negated 3
Speculated 1
Reported most in Abstract
Documents 14
Total Number 15
Disease Relevance 5.56
Pain Relevance 5.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Gh) signal transduction (Gh) mitochondrion (Gh)
extracellular space (Gh) extracellular region (Gh) plasma membrane (Gh)
Anatomy Link Frequency
plasma 2
ovary 2
Gh (Mus musculus)
Pain Link Frequency Relevance Heat
narcan 45 100.00 Very High Very High Very High
Opioid 18 100.00 Very High Very High Very High
antagonist 9 100.00 Very High Very High Very High
opiate 4 100.00 Very High Very High Very High
Clonidine 24 99.84 Very High Very High Very High
GABAergic 4 99.64 Very High Very High Very High
agonist 9 99.00 Very High Very High Very High
opioid receptor 2 96.72 Very High Very High Very High
Endogenous opioid 6 92.40 High High
Morphine 3 88.84 High High
Disease Link Frequency Relevance Heat
Disease 3 99.62 Very High Very High Very High
Hypoglycemia 12 99.20 Very High Very High Very High
Polycystic Ovary Syndrome 5 98.56 Very High Very High Very High
Obesity 20 98.48 Very High Very High Very High
Eating Disorder 16 98.40 Very High Very High Very High
Weight Loss 1 97.56 Very High Very High Very High
Depression 3 97.52 Very High Very High Very High
Stress 2 95.68 Very High Very High Very High
Growth Problems 4 87.60 High High
Hirsutism 1 85.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We studied the effect of the opiate antagonist naloxone on the peripheral GH response to the alpha 2-receptor agonist clonidine in eight normally cycling women during the mid-luteal phase.
Regulation (effect) of Regulation (response) of GH associated with antagonist, agonist, narcan, opiate and clonidine
1) Confidence 0.22 Published 1989 Journal Psychoneuroendocrinology Section Abstract Doc Link 2543999 Disease Relevance 0 Pain Relevance 0.74
These data suggest the involvement of a GABAergic mechanism in the regulation of GH and PRL responses to physical exercise in men.
Regulation (regulation) of Regulation (responses) of GH associated with gabaergic
2) Confidence 0.21 Published 1994 Journal Eur. J. Endocrinol. Section Abstract Doc Link 8038904 Disease Relevance 0 Pain Relevance 0.82
In order to verify this hypothesis we studied the effect of iv naloxone, an opiate receptor antagonist, on GH, PRL and cortisol response to insulin-induced hypoglycemia in 9 obese female subjects.
Regulation (effect) of Regulation (response) of GH associated with hypoglycemia, antagonist, obesity, narcan and opiate
3) Confidence 0.20 Published 1989 Journal J. Endocrinol. Invest. Section Abstract Doc Link 2693516 Disease Relevance 0.78 Pain Relevance 0.52
Naloxone did not modify the PRL and GH response but provoked a rise in the cortisol response in both obese and normal weight subjects.
Neg (not) Regulation (modify) of Neg (not) Regulation (response) of GH associated with obesity and narcan
4) Confidence 0.20 Published 1989 Journal J. Endocrinol. Invest. Section Abstract Doc Link 2693516 Disease Relevance 0.85 Pain Relevance 0.57
A neuropharmacologic approach was utilized to investigate the catecholaminergic influence on the hypothalamic regulation of growth hormone (GH) secretion in young (6-week-old) male domestic fowl.
Spec (investigate) Regulation (influence) of Spec (investigate) Regulation (regulation) of GH
5) Confidence 0.20 Published 1984 Journal Gen. Comp. Endocrinol. Section Abstract Doc Link 6735152 Disease Relevance 0 Pain Relevance 0.12
Our data indicate that alpha 2-adrenoceptors involved in the control of GH and adrenocorticotropic hormone are not altered in AN.
Regulation (involved) of Regulation (control) of GH associated with eating disorder
6) Confidence 0.18 Published 1987 Journal Psychiatry Res Section Abstract Doc Link 2951760 Disease Relevance 0.84 Pain Relevance 0.36
Opioid dysregulation after biliopancreatic diversion: effect of naloxone on preprandial and postprandial growth hormone (GH)-releasing hormone-induced GH release in surgically induced weight loss.
Regulation (effect) of Regulation (dysregulation) of GH associated with weight loss, narcan and opioid
7) Confidence 0.14 Published 2001 Journal Metab. Clin. Exp. Section Title Doc Link 11288030 Disease Relevance 0.90 Pain Relevance 0.44
In conclusion, patients with only mild to moderate degree of Alzheimer's disease have no prominent changes in GH regulation.
Neg (no) Regulation (changes) of Regulation (regulation) of GH associated with disease
8) Confidence 0.13 Published 1992 Journal Neurobiol. Aging Section Abstract Doc Link 1522942 Disease Relevance 0.23 Pain Relevance 0.12
In a replicated 4 x 4 latin square, the effects of intravenous naloxone on PRL and GH responses was tested in young (86 +/- 11 d) and older (234 +/- 6 d) heifers.
Regulation (effects) of Regulation (responses) of GH associated with narcan
9) Confidence 0.13 Published 1990 Journal J. Anim. Sci. Section Abstract Doc Link 2384365 Disease Relevance 0 Pain Relevance 0.82
Influence of naloxone infusion on prolactin and growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
Regulation (Influence) of Regulation (response) of growth hormone associated with narcan and eating disorder
10) Confidence 0.07 Published 1991 Journal Psychoneuroendocrinology Section Title Doc Link 1811245 Disease Relevance 0.52 Pain Relevance 0.35
The effect of naloxone, a specific antagonist of opioid peptides, on plasma, GH, PRL, and cortisol responses to insulin-induced hypoglycemia was studied in five healthy male subjects.
Regulation (effect) of Regulation (responses) of GH in plasma associated with hypoglycemia, antagonist, narcan and opioid
11) Confidence 0.05 Published 1980 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6987258 Disease Relevance 0.40 Pain Relevance 0.33
In conclusion, our data are consistent with the hypothesis of the existence of a complex derangement of GH neuroendocrine regulation in these subjects.
Regulation (derangement) of Regulation (regulation) of GH
12) Confidence 0.04 Published 1996 Journal J. Endocrinol. Invest. Section Abstract Doc Link 9007701 Disease Relevance 0.21 Pain Relevance 0.14
A central influence on neurotransmitter control of GH might be hypothesised.
Regulation (influence) of Regulation (control) of GH
13) Confidence 0.02 Published 1997 Journal Eur. J. Endocrinol. Section Body Doc Link 9437228 Disease Relevance 0 Pain Relevance 0
Serum IGF-I increased from 67.4+/-70.6 to 98.2+/-77.3 ng/ml (p <0.001), IGFBP-3 from 2326+/-770 to 2758+/-826 ng/ml (p <0.001), alkaline phosphatase from 525+/-136 to 666+/-197 U/l (p <0.0001), and osteocalcin from 16.8+/-10.6 to 25.8+/-12.8 ng/ml (p <0.05) after zinc supplementation despite there being no difference in GH response to clonidine after zinc supplementation (peak GH 11.6+/-6.9 vs 13.4+/-7.8 ng/ml, GH area under the curve during clonidine test 689+/-395 vs 761+/-468, NS).
Neg (no) Regulation (difference) of Regulation (response) of GH associated with clonidine
14) Confidence 0.01 Published 2005 Journal J. Pediatr. Endocrinol. Metab. Section Abstract Doc Link 15679071 Disease Relevance 0.24 Pain Relevance 0.28
Influence of leptin, androgens and insulin sensitivity on increased GH response to clonidine in lean patients with polycystic ovary syndrome.
Regulation (Influence) of Regulation (response) of GH in ovary associated with polycystic ovary syndrome and clonidine
15) Confidence 0.01 Published 2005 Journal Horm. Metab. Res. Section Title Doc Link 15778926 Disease Relevance 0.57 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox